About Us
The people behind NAD⁺airX®
Driven by science, built on experience - meet the leaders pioneering accessible NAD⁺ therapy for the world.
CEO & Founder, NADclinic Group
Iain De Havilland
Iain De Havilland is a visionary entrepreneur and pioneer in NAD⁺ therapy, longevity science, and precision wellness. He is the CEO and founder of the NADclinic Group, one of the world's leading producers of premium NAD⁺ therapeutics, peptides, and longevity medicine, and a recognised global leader in regenerative cellular health.
Iain first encountered NAD⁺ while co-founding a five-star rehabilitation centre in Europe, where he introduced NAD⁺ injectable therapy as a groundbreaking treatment for executive burnout and lifestyle detoxification. After witnessing the powerful clinical outcomes firsthand and becoming a regular NAD⁺ IV user himself, he recognised its potential as a much broader intervention for cellular rejuvenation, human performance, and healthy ageing.
This discovery led to several years of intensive research and development into NAD⁺ as a longevity and metabolic optimisation therapy. Working alongside leading orthomolecular physicians, clinicians, and scientists, Iain developed a range of proprietary protocols targeting anti-senescence, human performance, and optimised healthspan.
Co-Founder and CEO, NADairX®
Erin Lee
Erin Lee is a wellness entrepreneur, founder, and global advisor dedicated to enhancing healthspan and democratising access to science-backed wellness technologies that optimise recovery, performance, and longevity. She operates at the intersection of respiratory physiology, product engineering, and scalable wellness infrastructure, with a focus on making advanced wellness solutions more accessible and practical for global markets.
Erin is the Co-Founder & CEO of NADairX, alongside Iain De Havilland, where she is helping lead the development of a dry powder inhaler (DPI) platform exploring pulmonary delivery of NAD⁺. Built on inhalation science and controlled particle engineering principles, the platform is designed to support consistent, repeatable use within a regulatory-conscious framework. Positioned as a complementary, non-invasive format within the broader NAD⁺ ecosystem, its ambition is to expand access to advanced supplementation models while reducing the infrastructure complexity associated with injectable formats.
She is also the Founder of the Touchless Wellness Association (TWA), an initiative focused on advancing education, innovation, and accessibility within the global wellness sector. Through this work, Erin advocates for the development and adoption of high-impact, touch-free therapies that combine emerging technologies with practical, real-world applications.
Our Mission
To make next-generation NAD⁺ therapy accessible, non-invasive, and science-driven - empowering people everywhere to take control of their cellular health and longevity.